▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #483 by analyst upside · 2026-09-27
PMVP
PMV Pharmaceuticals, Inc.
Healthcare · Market Cap $71M · P/E 0x
ANALYST PRICE TARGET
+215.8%
implied upside to consensus target
Current Price $1.33
Consensus Target $4.2
Bull Target $5.0
Bear Target $3.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
5
Hold
0
Sell
0
52-Week Low $1.02
52-Week High $1.88
YTD Return +8.1%
FUNDAMENTALS
Market Cap $71M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.42
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.02
52-Week High $1.88
Current Price $1.33
Bear Target $3.0
Bull Target $5.0
● Now $1.33 ● Target $4.2
TRADING DATA
Avg Volume 515K
YTD Return +8.1%
Analyst Count 5
Consensus Buy
Upside to Target +215.8%
Last Updated 2026-09-27

ANALYST SUMMARY

PMV Pharmaceuticals, Inc. (PMVP) is currently trading at $1.33 with a Wall Street consensus price target of $4.2, implying potential upside of 215.8% over the next 12 months. 5 analysts currently cover PMVP, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $5.0, while the most cautious has a target of $3.0.

PMVP operates in the Healthcare sector with a market capitalisation of $71M. The stock is up 8.1% year-to-date and is currently trading near the lower end of its 52-week range of $1.02 – $1.88.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ELOX +154.5%
Eloxx Pharmaceuticals, Inc.
$52M · P/E 4.3x · Buy
CCLD +257.7%
CareCloud, Inc.
$87M · P/E 29.3x · Strong Buy
SPRO +306.5%
Spero Therapeutics, Inc.
$72M · P/E 8.8x · Buy
FBIO +119.3%
Fortress Biotech, Inc.
$76M · P/E 0.8x · Buy
ATNM +200.0%
Actinium Pharmaceuticals, Inc.
$38M · P/E 3.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PMVP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-09-04 31% win rate (48 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-05-13 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-20 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-08-20 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →